Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vaxcyte Inc (NQ: PCVX ) 116.23 +0.95 (+0.82%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,152,725 Open 116.50 Bid (Size) 107.00 (1) Ask (Size) 121.20 (1) Prev. Close 115.28 Today's Range 113.77 - 119.50 52wk Range 44.20 - 119.50 Shares Outstanding 93,706,790 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares September 06, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Announces Pricing of $1.3 Billion Public Offering September 04, 2024 From Vaxcyte, Inc. Via GlobeNewswire Performance YTD +84.67% +84.67% 1 Month +48.82% +48.82% 3 Month +60.14% +60.14% 6 Month +62.29% +62.29% 1 Year +121.73% +121.73% More News Read More Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants September 03, 2024 From Vaxcyte, Inc. Via GlobeNewswire Peering Into Vaxcyte's Recent Short Interest August 27, 2024 Via Benzinga Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session September 03, 2024 Via Benzinga Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday September 03, 2024 Via Benzinga PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024 May 08, 2024 Via InvestorPlace Recap: Vaxcyte Q4 Earnings February 27, 2024 Via Benzinga Earnings Scheduled For February 27, 2024 February 27, 2024 Via Benzinga Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher September 03, 2024 Via Benzinga Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market September 03, 2024 Via Investor's Business Daily Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older September 03, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older September 02, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update August 06, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Appoints John Furey to Board of Directors July 02, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update May 08, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says April 10, 2024 Via Benzinga Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From Vaxcyte, Inc. Via GlobeNewswire Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday March 12, 2024 Via Benzinga Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants March 04, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update February 27, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 February 15, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares February 02, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference February 01, 2024 From Vaxcyte, Inc. Via GlobeNewswire Vaxcyte Announces Pricing of $750 Million Public Offering January 30, 2024 From Vaxcyte, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
